Martin Allen-Auerbach

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma
    Martin Allen-Auerbach
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 6942 USA
    Mol Imaging Biol 6:411-6. 2004
  2. doi request reprint PET/computed tomography and lymphoma
    Martin Allen-Auerbach
    Ahmanson Translational Imaging Division Nuclear Medicine, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095 6948, USA Electronic address
    Radiol Clin North Am 51:833-44. 2013
  3. pmc Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin's lymphoma
    Barbara J Fueger
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Mol Imaging Biol 11:269-74. 2009
  4. doi request reprint Measuring response with FDG-PET: methodological aspects
    Martin Allen-Auerbach
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, CA 90095 6942, USA
    Oncologist 14:369-77. 2009
  5. ncbi request reprint Standard PET/CT of the chest during shallow breathing is inadequate for comprehensive staging of lung cancer
    Martin Allen-Auerbach
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, California, USA
    J Nucl Med 47:298-301. 2006
  6. ncbi request reprint Evaluation of suspected local recurrence in head and neck cancer: a comparison between PET and PET/CT for biopsy proven lesions
    Benjamin S Halpern
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center Nuclear Medicine, UCLA School of Medicine, Los Angeles, CA 90095 6948, USA
    Eur J Radiol 62:199-204. 2007
  7. ncbi request reprint Accuracy of PET/CT in characterization of solitary pulmonary lesions
    Shanna K Kim
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California 90095 6942, USA
    J Nucl Med 48:214-20. 2007
  8. doi request reprint The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients
    Martin Allen-Auerbach
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center Nuclear Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095 6948, USA
    Radiol Clin North Am 46:199-211, vii. 2008
  9. ncbi request reprint Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006
    Johannes Czernin
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic Nuclear Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California 90095 6948, USA
    J Nucl Med 48:78S-88S. 2007
  10. doi request reprint Oncologic 18F-FDG PET/CT: referring physicians' point of view
    Dimitrios Karantanis
    Department of Molecular and Medical Pharmacology, Ahmanson Translational Imaging Division, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    J Nucl Med 53:1499-505. 2012

Detail Information

Publications15

  1. ncbi request reprint Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma
    Martin Allen-Auerbach
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 6942 USA
    Mol Imaging Biol 6:411-6. 2004
    ..We sought to determine whether integrated (hardware) fused PET/CT imaging results in further improvements in staging accuracy...
  2. doi request reprint PET/computed tomography and lymphoma
    Martin Allen-Auerbach
    Ahmanson Translational Imaging Division Nuclear Medicine, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095 6948, USA Electronic address
    Radiol Clin North Am 51:833-44. 2013
    ..Its ability to characterize masses as benign or malignant and its high sensitivity and specificity for staging, restaging, and treatment monitoring have led to widespread acceptance of PET imaging for managing patients with lymphoma...
  3. pmc Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin's lymphoma
    Barbara J Fueger
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Mol Imaging Biol 11:269-74. 2009
    ..The aim was to investigate the potential impact of positron emission tomography (PET)/computed tomography (CT) as compared to PET and CT on the staging of patients with indolent lymphoma...
  4. doi request reprint Measuring response with FDG-PET: methodological aspects
    Martin Allen-Auerbach
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, CA 90095 6942, USA
    Oncologist 14:369-77. 2009
    ..The aim of this review is to provide oncologists with a basic knowledge of the practical aspects of PET quantification for treatment...
  5. ncbi request reprint Standard PET/CT of the chest during shallow breathing is inadequate for comprehensive staging of lung cancer
    Martin Allen-Auerbach
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, California, USA
    J Nucl Med 47:298-301. 2006
    ..Micronodules are usually too small to be characterized reliably with 18F-FDG PET. We aimed to determine the incidence of missed pulmonary micronodules on PET/CT studies acquired during shallow breathing...
  6. ncbi request reprint Evaluation of suspected local recurrence in head and neck cancer: a comparison between PET and PET/CT for biopsy proven lesions
    Benjamin S Halpern
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center Nuclear Medicine, UCLA School of Medicine, Los Angeles, CA 90095 6948, USA
    Eur J Radiol 62:199-204. 2007
    ..18)F-FDG PET has a high accuracy for re-staging of head and neck cancer. The purpose of this study was to determine whether the diagnostic accuracy can be further improved with integrated PET/CT...
  7. ncbi request reprint Accuracy of PET/CT in characterization of solitary pulmonary lesions
    Shanna K Kim
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California 90095 6942, USA
    J Nucl Med 48:214-20. 2007
    ..The performance of dual-modality imaging with PET/CT for characterizing SPNs was investigated in a clinical referral setting...
  8. doi request reprint The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients
    Martin Allen-Auerbach
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center Nuclear Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095 6948, USA
    Radiol Clin North Am 46:199-211, vii. 2008
    ..PET/CT has evolved to become the modality of choice for staging of nodal and extranodal lymphoma, for assessing therapeutic response, and for establishing patient prognosis...
  9. ncbi request reprint Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006
    Johannes Czernin
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic Nuclear Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California 90095 6948, USA
    J Nucl Med 48:78S-88S. 2007
    ..From these data, we believe, has emerged reliable evidence in support of the notion that PET/CT offers diagnostic advantages over its individual components for the major cancers...
  10. doi request reprint Oncologic 18F-FDG PET/CT: referring physicians' point of view
    Dimitrios Karantanis
    Department of Molecular and Medical Pharmacology, Ahmanson Translational Imaging Division, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    J Nucl Med 53:1499-505. 2012
    ..However, the referring physician's attitude toward the usefulness of this diagnostic modality is unknown. This survey was undertaken to collect information regarding the current perspective of referring physicians on oncologic PET/CT...
  11. doi request reprint Squamous papilloma of the oral cavity and oropharynx on 18F-FDG PET/CT imaging
    Dimitrios Karantanis
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Clin Nucl Med 37:e98-9. 2012
    ..This benign entity should be included in the differential diagnosis of FDG-positive oral and oropharyngeal lesions...
  12. pmc Computer-aided quantitative bone scan assessment of prostate cancer treatment response
    Matthew S Brown
    Department of Radiological Sciences, Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine at UCLA, University of California, Los Angeles, California 90024, USA
    Nucl Med Commun 33:384-94. 2012
    ..The development and evaluation of a computer-aided bone scan analysis technique to quantify changes in tumor burden and assess treatment effects in prostate cancer clinical trials...
  13. doi request reprint Relationship among glycolytic phenotype, grade, and histological subtype in ovarian carcinoma
    Dimitrios Karantanis
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Clin Nucl Med 37:49-53. 2012
    ..This study was performed to determine the influence of tumor grade and histology on the glycolytic phenotype of epithelial ovarian cancer patients...
  14. doi request reprint Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients?
    Franziska Walter
    Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA
    J Pediatr Hematol Oncol 34:131-6. 2012
    ..It is unknown whether the combination of both tests results in more accurate detection of bone lesions than (18)F-FDG- PET/CT alone...
  15. doi request reprint Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas
    Vladimir Evilevitch
    Abteilung Nuklearmedizin University of Freiburg, Freiburg, Germany
    Clin Cancer Res 14:715-20. 2008
    ..The aim of this study was to prospectively evaluate whether positron emission tomography with (18)F-fluorodeoxyglucose (FDG-PET) allows for a more accurate evaluation of histopathologic response...